California-based TurtleTree has received a “No Questions” letter from the U.S. FDA in response to the company’s GRAS (Generally Recognized as Safe) dossier, validating the safety of its precision-fermented lactoferrin (LF+) for use in food.
According to TurtleTree, this marks the first time any regulatory body worldwide has approved this bioactive milk protein produced through precision fermentation, a breakthrough that redefines what’s possible in sustainable nutrition.
The FDA validation gives larger brands the confidence to formulate with LF+, removes regulatory uncertainty, and helps pave the way for global market expansion. The company’s GRAS dossier underwent extensive review, including structural, functional, and genomic studies, along with robust compositional data.
Lactoferrin is a highly complex, rare iron-binding glycoprotein celebrated for its role in immunity, gut health and iron regulation. Traditionally available only in trace amounts, mainly for infant nutrition due to high extraction costs, the protein has remained out of reach for broader use. TurtleTree’s LF+, produced through a proprietary precision fermentation process, delivers a scalable, animal-free source of lactoferrin now available for applications in adult nutrition, wellness supplements and functional food.
TurtleTree says it is already in conversations with several partners, and this milestone is expected to accelerate the rollout of new LF+ powered products in the near future. It also strengthens TurtleTree’s position as the company pursues regulatory pathways in other key markets, including Europe and Asia.